Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New protocol aims to ease suffering for ventilator patients at end of life

NCT ID NCT07368010

Symptom relief Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a structured palliative care protocol, combined with staff training, can improve end-of-life care for ICU patients on ventilators. Researchers will compare the protocol to usual care across multiple centers. The goal is to ensure patients are comfortable and families are supported when life support is withdrawn.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
palliative care protocol and staff training
What this could lead to
If it works, this could improve comfort and dignity for dying ICU patients and reduce suffering for families.
What could go wrong
This is a behavioral intervention, not a drug; results depend on staff adherence and may not change outcomes significantly. It is also not yet recruiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 720 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient: * Age ≥ 18 years * ICU admission for more than 48 hours * Receiving invasive mechanical ventilation * A documented decision to withdraw life-sustaining therapies, made through a multidisciplinary collegial process and communicated to the designated surrogate decision-maker, family, or relatives * At least one visit from a relative prior to the decision to withdraw life-sustaining therapies * Provision of informed consent for study participation, or, if the patient lacks decision-making capacity, consent obtained from a relative or legally authorized representative * Relative: * Age ≥ 18 years * Has received at least one medical update regarding the patient's clinical status from an ICU physician prior to the decision to withdraw life-sustaining therapies * Has provided informed consent for study participation Exclusion Criteria: * Patient: * Presence of a tracheostomy * Brain death or involvement in an organ donation procedure * Absence of any visit from a relative * Subject to legal guardianship or other legal protection measures * Incarcerated patient * Participation in another interventional research study focused on end-of-life care * Pregnant or breastfeeding woman * Relative: * Inability to understand or speak French * Subject to legal guardianship or other legal protection measures

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dying process are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Death

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dying process Intensive care medicine Palliative care Sedation Withdrawal of life support

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Nantes

    Nantes, 44, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.